• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.

作者信息

van de Donk Niels W C J, Bahlis Nizar, Costa Luciano J, Mateos María-Victoria, Nooka Ajay K, Perrot Aurore, Garfall Alfred L, Thaman Pragya, Qi Keqin, Uhlar Clarissa, Chastain Katherine, Doyle Margaret, Usmani Saad Z

机构信息

Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.

出版信息

Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1.

DOI:10.1038/s41408-024-01160-1
PMID:39433732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11494165/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf96/11494165/14338247c4ed/41408_2024_1160_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf96/11494165/14338247c4ed/41408_2024_1160_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf96/11494165/14338247c4ed/41408_2024_1160_Fig1_HTML.jpg

相似文献

1
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.在1/2期MajesTEC-1研究中，COVID-19对复发/难治性多发性骨髓瘤患者使用替西帕单抗治疗结局的影响。
Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1.
2
Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤患者中teclistamab的给药剂量：来自MajesTEC-1研究的建模与模拟结果
Target Oncol. 2025 May 7. doi: 10.1007/s11523-025-01149-1.
3
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.特卡昔单抗，一种 B 细胞成熟抗原 × CD3 双特异性抗体，用于治疗复发或难治性多发性骨髓瘤（MajesTEC-1）：一项多中心、开放标签、单臂、1 期研究。
Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.
4
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.复发/难治性多发性骨髓瘤细胞因子释放综合征的护理注意事项：MajesTEC-1 研究中特西他单抗的经验。
Semin Oncol Nurs. 2024 Jun;40(3):151621. doi: 10.1016/j.soncn.2024.151621. Epub 2024 Apr 9.
5
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.马吉斯特克-1（MajesTEC-1）研究的通俗易懂总结：teclistamab用于治疗复发或难治性多发性骨髓瘤患者。
Future Oncol. 2023 Apr;19(12):811-818. doi: 10.2217/fon-2023-0171. Epub 2023 May 3.
6
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.在MajesTEC-1研究中接受替西妥单抗治疗复发/难治性多发性骨髓瘤患者的感染发生率、发生时间及管理
Cancer. 2024 Mar 15;130(6):886-900. doi: 10.1002/cncr.35107. Epub 2023 Nov 14.
7
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.在 Prospective LocoMMotion 研究中，三药暴露复发和/或难治性多发性骨髓瘤患者的真实世界临床实践中，替西罗莫司与现有治疗方案的疗效比较。
Adv Ther. 2023 May;40(5):2412-2425. doi: 10.1007/s12325-023-02480-7. Epub 2023 Mar 24.
8
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.特西珠单抗治疗复发/难治性多发性骨髓瘤患者的群体药代动力学和暴露-反应：MajesTEC-1 研究结果。
Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15.
9
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.在三药暴露复发/难治性多发性骨髓瘤中，特里斯他单抗与现实世界中医生治疗选择的比较疗效：LocoMMotion 和 MoMMent 研究。
Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
10
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.在中国MajesTEC-1队列的复发/难治性多发性骨髓瘤患者中，替西妥单抗的疗效、安全性和药代动力学。
Cancer. 2025 Jan 1;131(1):e35665. doi: 10.1002/cncr.35665. Epub 2024 Dec 11.

引用本文的文献

1
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].埃拉纳单抗治疗复发或难治性多发性骨髓瘤患者的经济影响[信函]
Clinicoecon Outcomes Res. 2025 Jul 30;17:535-536. doi: 10.2147/CEOR.S550970. eCollection 2025.
2
[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)].《BCMA双特异性T细胞衔接器治疗多发性骨髓瘤中国临床专家共识（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):209-215. doi: 10.3760/cma.j.cn121090-20250202-00050.

本文引用的文献

1
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.在三药暴露复发/难治性多发性骨髓瘤中，特里斯他单抗与现实世界中医生治疗选择的比较疗效：LocoMMotion 和 MoMMent 研究。
Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
2
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.在MajesTEC-1研究中接受替西妥单抗治疗复发/难治性多发性骨髓瘤患者的感染发生率、发生时间及管理
Cancer. 2024 Mar 15;130(6):886-900. doi: 10.1002/cncr.35107. Epub 2023 Nov 14.
3
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.
在多发性骨髓瘤的整个病程中感染率都很高，不仅仅是使用双特异性抗体时如此。
Eur J Cancer. 2023 Aug;189:112926. doi: 10.1016/j.ejca.2023.05.014. Epub 2023 Jun 10.
4
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.嵌合抗原受体 T 细胞和双特异性抗体治疗多发性骨髓瘤期间感染预防的建议。
Br J Haematol. 2023 Dec;203(5):736-746. doi: 10.1111/bjh.18909. Epub 2023 Jun 7.
5
The potential link between Covid-19 and multiple myeloma: A new saga.新冠病毒与多发性骨髓瘤之间的潜在联系：一个新的传说。
Immun Inflamm Dis. 2022 Dec;10(12):e701. doi: 10.1002/iid3.701.
6
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
7
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.共识指南和建议，用于多发性骨髓瘤的感染预防：国际骨髓瘤工作组的报告。
Lancet Haematol. 2022 Feb;9(2):e143-e161. doi: 10.1016/S2352-3026(21)00283-0.
8
Impact of COVID-19 in patients with multiple myeloma based on a global data network.基于全球数据网络的 COVID-19 对多发性骨髓瘤患者的影响。
Blood Cancer J. 2021 Dec 10;11(12):198. doi: 10.1038/s41408-021-00588-z.
9
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.COVID-19 疫苗接种在多发性骨髓瘤患者中的应用：欧洲骨髓瘤网络共识。
Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
10
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.COVID-19 疫苗研发进展：病毒、疫苗和变体与疗效、有效性和逃逸。
Nat Rev Immunol. 2021 Oct;21(10):626-636. doi: 10.1038/s41577-021-00592-1. Epub 2021 Aug 9.